ASCO 2018 | JAVELIN Merkel 200: avelumab for metastatic Merkel cell carcinoma

Paul Nghiem

Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after 1-2 years, representing a great unmet need. Here, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the preliminary results of the Phase II JAVELIN Merkel 200 trial (NCT02155647) evaluating the efficacy and safety of avelumab for chemotherapy-refractory MCC. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter